<DOC>
	<DOCNO>NCT01417143</DOCNO>
	<brief_summary>The purpose phase II study TKI258 ( Dovitinib ) adenoid cystic carcinoma evaluate efficacy TKI258 ( Dovitinib ) .</brief_summary>
	<brief_title>Dovitinib Adenoid Cystic Carcinoma</brief_title>
	<detailed_description>open , uncontrolled , multi-center , phase II study</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<criteria>Histologically cytologically confirm adenoid cystic carcinoma Local , locally advanced metastatic disease document show progression scan ( CT , MRI , MIBI scan ) take 2 12 month prior baseline compare previous scan take time past . Progression must document accord RECIST criterion . Disease amenable surgery , radiation combine modality therapy curative intent previously treat chemotherapy local treatment ( e.g . transarterial chemoembolization ) Presence least one measurable target lesion evaluation accord RECIST criterion 18 year old ECOG performance status 0 , 1 Previous treatment chemotherapy , target agent , locoregional therapy ( e.g . chemoembolization ) permit provide toxicity resolve &lt; = grade 1 study entry last treatment least 4 week prior baseline assessment . Adequate organ function A patient willingness comply study protocol study period capable comply A patient sign informed consent prior participation study understand right withdrawal participation study time without disadvantage . A patient measurable disease Prior chemotherapy , radiation therapy surgery within 4 week prior study entry except palliative radiotherapy nontarget lesion ( within 2 week prior study entry ) A patient previous active passive immunotherapy A patient intestinal obstruction impend obstruction , recent active upper GI bleed A pregnant lactating patient A patient childbearing potential without tested pregnancy baseline test positive . ( A postmenopausal woman amenorrhea period least 12 month longer consider nonchildbearing potential ) A man woman childbearing potential willingness use contraceptive measure study A patient history another malignant disease within past 5 year , except curatively treat basal cell carcinoma skin cervical carcinoma situ . A patient history uncontrolled seizure , central nervous system disorder psychiatric disorder consider clinically significant investigator would prohibit understanding informed consent may consider interfere compliance administration study medication . A patient clinically significant heart disease ( e.g . congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia , etc ) myocardial infarction within past 12 month . Ongoing cardiac arrhythmia grade &gt; = 2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female . A patient interstitial pneumonia diffuse symptomatic fibrosis lungs A patient peripheral neuropathy grade 1 NCI CTC , cause factor ( e.g . alcohol , diabetes , etc ) . If absence deep tendon reflex neurologic disorder , condition apply exclusion criterion . A patient organ transplantation require immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>dovitinib</keyword>
</DOC>